---
title: "Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296370263.md"
description: "Jiangsu Hengrui Pharmaceuticals approved a 2026 employee stock ownership plan using existing A-shares, not new equity. The scheme aims to align interests and enhance competitiveness. It involves directors and senior management but falls below thresholds requiring shareholder approval. Analysts rate the stock as 'Buy' with a HK$92 target."
datetime: "2026-08-19T14:15:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296370263.md)
  - [en](https://longbridge.com/en/news/296370263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296370263.md)
generator: "portal-rs"
---

# Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares

An update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.

Jiangsu Hengrui Pharmaceuticals has approved a 2026 A share employee stock ownership scheme, which will take effect upon shareholder approval and will use existing A shares rather than issuing new equity or options. The programme aims to align the interests of employees, shareholders and the company, enhancing motivation, cohesion and competitiveness to support long-term sustainable growth.

Under Hong Kong listing rules, the scheme falls within provisions governing employee share plans involving existing shares and includes participation by certain directors and the chief executive, technically making it a connected transaction. However, the relevant ratios are below the threshold requiring shareholder approval or additional disclosure, and broader employee participation will proceed on a voluntary, compliant basis for directors, senior management, core personnel and other staff identified by the board.

The most recent analyst rating on (HK:1276) stock is a Buy  
 with a HK$92.00 price target.  
 To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock,  
 see the HK:1276 Stock Forecast page. 

**More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H**

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based joint stock company listed in Hong Kong that operates in the pharmaceutical industry. The company focuses on the development, manufacturing and sale of medicines, with a workforce that includes directors, senior management and key technical and operational staff across its subsidiaries.

**Average Trading Volume:** 4,155,622

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$404.1B

### Related Stocks

- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Sinotrans to Host Online Briefing on 2026 Interim Results](https://longbridge.com/en/news/296215454.md)
- [LEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain](https://longbridge.com/en/news/296217400.md)
- [11:06 ETPeptide Synthesis Market: USD 2.59 Billion by 2031, Driven by Therapeutic Demand & Advanced Synthesis Technologies, Says Mordor Intelligence](https://longbridge.com/en/news/296247020.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**